Sapience Targets 'Undruggable' Cancers, Courts Investors at Key Summit

TARRYTOWN, N.Y. – April 13, 2026 – As the 25th Annual Needham Virtual Healthcare Conference kicks off this week, clinical-stage biotech firm Sapience Therapeutics is positioning itself at the intersection of scientific innovation and strategic finance. The company announced its management will hold a series of one-on-one virtual meetings with investors, a move that underscores a pivotal moment for a private company advancing a promising, but capital-intensive, pipeline of cancer therapies.

For a company like Sapience, which is tackling some of oncology's most notoriously difficult targets, this engagement is more than just a calendar entry. It represents a concerted effort to secure the resources needed to push its novel peptide therapeutics through late-stage clinical trials and toward potential market approval.

A New Arsenal Against Cancer

At the heart of investor interest is Sapience's unique scientific platform, designed to succeed where other drug modalities have failed. The company has developed proprietary therapeutic candidates called SPEARs™ (Stabilized Peptides Engineered Against Regulation), which are engineered to penetrate cells and disrupt protein-protein interactions that drive cancer growth. This approach allows Sapience to target transcription factors—master regulators of gene expression—that have long been considered 'undruggable' by traditional small-molecule drugs or larger antibodies.

The company’s pipeline is spearheaded by two assets currently in Phase 2 clinical trials, both of which have generated encouraging data in hard-to-treat cancers.

Its lead program, lucicebtide (formerly ST101), is a first-in-class antagonist of C/EBPβ, a protein implicated in tumor cell survival. The therapy is showing significant promise in glioblastoma (GBM), one of the most aggressive and deadly forms of brain cancer. Clinical data has demonstrated that lucicebtide can cross the formidable blood-brain barrier, engage its target, and remodel the tumor microenvironment from an immunosuppressive state to one that is active against cancer. In studies, lucicebtide has extended both progression-free survival and overall survival beyond historical benchmarks for patients with recurrent GBM. The U.S. Food and Drug Administration (FDA) has granted it Fast Track designation for this indication, highlighting the urgent need for new treatments.

Sapience's second clinical-stage candidate, ST316, targets a different oncogenic pathway. It is a first-in-class antagonist of the interaction between β-catenin and BCL9, a key driver in cancers with abnormal Wnt pathway signaling, such as certain colorectal cancers (CRC). The Phase 1 portion of its study showed ST316 was safe and well-tolerated, a critical differentiator from earlier Wnt-targeting agents that were hampered by toxicity. Furthermore, it demonstrated early signs of anti-tumor activity, with several patients experiencing prolonged stable disease, including one CRC patient for over 14 months. ST316 has also received an Orphan Drug Designation from the FDA for a rare hereditary condition, familial adenomatous polyposis (FAP).

Beyond its SPEARs™, the company is also developing SPARCs™ (Stabilized Peptides Against Receptors on Cancer), a platform designed to deliver potent payloads, such as alpha-particle radioisotopes, directly to cancer cells, further expanding its therapeutic toolkit.

The Strategic Push for Capital

While the science is compelling, advancing these therapies through the final stages of clinical development is an expensive endeavor. Sapience operates as a privately held company and has raised a total of $71.5 million to date. Its last major financing was a $41 million Series B round that closed in June 2022, led by NexPoint with participation from notable investors including Bristol Myers Squibb and Eshelman Ventures. Those funds were instrumental in advancing lucicebtide and ST316 into their current Phase 2 trials.

Now, nearly four years later, the company's active participation in the Needham conference signals a strategic initiative to prepare for its next phase of growth. The one-on-one investor meetings provide a crucial platform to present the latest clinical data and lay the groundwork for a future funding round, a strategic partnership with a larger pharmaceutical firm, or another significant financial event.

This strategic positioning is further reinforced by the strength of its leadership. Sapience's management team is composed of industry veterans with deep experience in drug development and corporate finance. Recent additions have further sharpened its business acumen. In late 2024, the company brought on Augustine Bourne as VP of Business Development, who previously led strategy at Mirati Therapeutics before its $5.8 billion acquisition by Bristol Myers Squibb. It also added Dr. Pamela Esposito to its board; Dr. Esposito has a track record of executive leadership at companies involved in major acquisitions, including Ra Pharmaceuticals and Mariana Therapeutics. Such hires suggest a deliberate strategy to maximize the value of its clinical assets as they mature.

Navigating a Competitive Peptide Landscape

Sapience is making its move within a dynamic and increasingly competitive sector. The market for peptide-based cancer therapeutics is booming, with projections estimating it will grow from approximately $26.5 billion in 2024 to over $70 billion by 2035. This growth is fueled by the inherent advantages of peptides, which can offer higher specificity and better safety profiles compared to conventional chemotherapy.

Major pharmaceutical giants and a host of innovative biotechs are active in this space, many focusing on peptide-drug conjugates (PDCs) that link a targeting peptide to a cytotoxic agent. However, Sapience's focus on disrupting intracellular protein-protein interactions with its SPEARs™ platform carves out a distinct and valuable niche. By successfully targeting proteins previously thought to be inaccessible, the company is not just competing but is aiming to redefine the boundaries of cancer therapy.

The outcomes of the investor meetings at this week's conference could be a determining factor in the company's ability to maintain its momentum. With promising data in hand and a clear strategy for addressing 'undruggable' targets, Sapience Therapeutics stands at a critical juncture, ready to translate its scientific breakthroughs into the capital required to bring a new generation of cancer treatments to patients in need.